Combining CTLA-4 blockade with the demethylating agent decitabine in a murine ovarian cancer model led to elevated differentiation of naïve into effector T cells, extended responses of cytotoxic lymphocytes, and prolonged mouse survival [57]. The gene discussed is CTLA4; the disease is ovarian carcinoma.